share_log

Johnson & Johnson | 3: Initial statement of beneficial ownership of securities-10% Owner JOHNSON & JOHNSON

Johnson & Johnson | 3: Initial statement of beneficial ownership of securities

強生 | 3：首次持股聲明
SEC announcement ·  04/11 05:06
牛牛AI助理已提取核心訊息
Johnson & Johnson, a major healthcare company, has filed an SEC Form 3 indicating an initial statement of beneficial ownership of securities. The filing, dated 04/09/2024, reveals that Johnson & Johnson, through its wholly-owned subsidiary Johnson & Johnson Innovation - JJDC, Inc., has become a 10% owner of Contineum Therapeutics, Inc., with an indirect beneficial ownership of 1,979,173 shares of Class A Common Stock. The document was signed by Marc Larkins, Secretary of Johnson & Johnson, and underscores the company's significant investment in Contineum Therapeutics.
Johnson & Johnson, a major healthcare company, has filed an SEC Form 3 indicating an initial statement of beneficial ownership of securities. The filing, dated 04/09/2024, reveals that Johnson & Johnson, through its wholly-owned subsidiary Johnson & Johnson Innovation - JJDC, Inc., has become a 10% owner of Contineum Therapeutics, Inc., with an indirect beneficial ownership of 1,979,173 shares of Class A Common Stock. The document was signed by Marc Larkins, Secretary of Johnson & Johnson, and underscores the company's significant investment in Contineum Therapeutics.
大型醫療保健公司強生公司已向美國證券交易委員會提交了3號表格，其中顯示了證券實益所有權的初步聲明。這份日期爲2024年9月4日的文件顯示，強生通過其全資子公司強生創新——JJDC, Inc. 已成爲Contineum Therapeutics, Inc. 的10％所有者，擁有1,979,173股A類普通股的間接實益所有權。該文件由強生公司秘書馬克·拉金斯簽署，強調了該公司對Contineum Therapeutics的重大投資。
大型醫療保健公司強生公司已向美國證券交易委員會提交了3號表格，其中顯示了證券實益所有權的初步聲明。這份日期爲2024年9月4日的文件顯示，強生通過其全資子公司強生創新——JJDC, Inc. 已成爲Contineum Therapeutics, Inc. 的10％所有者，擁有1,979,173股A類普通股的間接實益所有權。該文件由強生公司秘書馬克·拉金斯簽署，強調了該公司對Contineum Therapeutics的重大投資。
有用
沒用

該公告為獨立文件：

獨立文件1  查看翻譯

譯文內容由第三人軟體翻譯。


牛牛AI助手部分由第三方人工智慧模型基於資訊內容自動產生，只对除中国内地以外的地区提供。


以上內容僅用作資訊或教育之目的，不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。